INmune Bios Alzheimers Drug XPro Fails Mid-Stage Study, Shares Plummet 63%

INmune Bio’s experimental Alzheimer’s drug, XPro, failed to meet its primary goal in a mid-stage study, leading to a significant drop in the company’s shares. The drug, designed to target inflammatory signals associated with tumor necrosis factor without suppressing the immune system, did not improve cognitive functions in patients with early-stage Alzheimer’s disease. The study involved 208 patients with mild Alzheimer’s or mild cognitive impairment, who received either XPro or a placebo for 24 weeks. Although the drug was deemed safe and well-tolerated, with injection site reactions being the most common adverse event, the lack of efficacy in cognitive improvement resulted in a nearly 63% decline in INmune Bio’s stock during premarket trading.